RTP Mobile Logo
Summer Oncology Nursing Series: Gynecologic Cancer — Session 1 (Webinar Video Proceedings)
Released September 2021

Proceedings from a series of 11 summer webinars held following the 2021 ONS Annual Congress. Featuring perspectives from Dr Krishnansu S Tewari and Ms Courtney Arn. Published September 17, 2021. (Webinar Video Proceedings)

CE Disclosures and Faculty Information

    These activities have been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of gynecologic cancers.

    By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with gynecologic cancers.


    • Consider the FDA approvals of olaparib and niraparib as maintenance therapy after first-line platinum-based chemotherapy for advanced ovarian cancer (OC), and counsel patients with and without BRCA mutations regarding appropriate treatment recommendations.
    • Recognize the toxicities associated with the various commercially available PARP inhibitors commonly used in the care of patients with OC, and offer supportive management strategies to minimize and ameliorate these side effects.
    • Understand the importance of microsatellite instability (MSI) testing for patients with endometrial cancer, and identify the benefits observed with anti-PD-1/PD-L1 antibodies for MSI-high or mismatch repair-deficient disease.
    • Discuss the efficacy of pembrolizumab in combination with lenvatinib, recognize the toxicities associated with this combination in the management of advanced, recurrent endometrial cancer, and offer supportive management strategies to minimize and ameliorate these side effects.
    • Consider the potential role of the novel agent tisotumab vedotin in exploiting tissue factor expression in patients with cervical cancer.
    • Appraise clinical research findings supporting the efficacy of anti-PD-1 monotherapy for patients with progressing PD-L1-positive cervical cancer.
    • Assess the toxicities associated with immune checkpoint inhibitors and other novel agents used to manage gynecologic cancers, and offer patients supportive management strategies to minimize and ameliorate these side effects.

    Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

    NCPD credit is no longer available for this issue

    NCPD credit is no longer available for this issue

    Audio Program: This NCPD activity consists of an audio component.
    NCPD credit is no longer available for this issue

    Video Program: This NCPD activity consists of a video component.
    NCPD credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Krishnansu S Tewari, MD
    Division of Gynecologic Oncology
    University of California, Irvine
    Irvine, California

    Advisory Committee: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Merck, Tesaro, A GSK Company; Contracted Research (to Institution): Regeneron Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: Iovance Biotherapeutics; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Merck, Tesaro, A GSK Company.

    Courtney Arn, CNP
    The James Cancer Hospital and Solove Research Institute
    The Ohio State University
    Columbus, Ohio

    No relevant conflicts of interest to disclose.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

    RTP NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

    These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Eisai Inc, GlaxoSmithKline and Merck.

    Release date: September 2021
    Expiration date: September 2022

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):